Welcome!

News Feed Item

Medical Devices Industry and Market Prospects 2013-2023

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Medical Devices Industry and Market Prospects 2013-2023

Report Details

Medical devices - your guide to developments, opportunities, and revenues
What does the future hold for medical devices? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and prospects in this market.

Our study gives you revenue forecasts to 2023 at overall world market and national level. There you see financial results, interviews, trends, opportunities, and revenue predictions. You also gain 64 figures, 57 tables and three interviews with authorities in the industry.

Prospects for leading countries shown to 2023

Regulatory, demographic and commercial developments worldwide will influence the market, especially fast-rising demand in emerging markets.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:
• US
Japan
Germany, France, UK, Italy and Spain (EU5 nations)
• BRIC nations - Brazil, Russia, India, and China

Many commercial opportunities exist in developed and developing countries. Our study explains, assessing progress and prospects.
There you assess the medical device industry's future - hear about developments and find their significance.

Companies and overall 2017 market value - what predicted revenue?

Our report predicts the world market for medical devices will reach $398bn in 2017 and expand further to 2023.
Our work shows you which technologies and organisations hold greatest potential.

In particular, you explore these organisations:
• Johnson and Johnson
• GE Healthcare
• Siemens Healthcare
• Medtronic
• Baxter International
• Philips Healthcare
• Roche
• Abbott Laboratories
• Stryker Corporation
• Becton, Dickinson & Co.

In general, a company profile gives you the following information:
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations
• Medical device revenue forecasts to 2023

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting for two important medical device submarkets:
• Cardiology Devices
• Neurology Devices

That investigation also discusses sectors within those submarkets. You discover revenue forecasts to 2023 for the following sectors:
• The drug eluting stents market
• Neuromodulation devices (including SCS, DBS and VNS markets).

See how and why those sectors can prosper. You see prospects for established and emerging technologies and competition.

Issues affecting the manufacturing and selling of medical devices

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:
• The medical device excise tax - hampering innovation?
• Strong government support across major international markets - driving growth
• Market driven by an aging population
• Market susceptibility to economic pressures
• International expansion - targeting emerging national markets
• Comparative effectiveness research as an added expense
• Large number of participating companies - increasing rivalry among competitors

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Ways Medical Devices Industry and Market Prospects 2013-2023 helps you

In summary, our report gives you the following knowledge:
• Revenues to 2023 for the overall world market - discover that industry's prospects, finding promising areas for investments and revenues
• Assess 11 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia
• Prospects for cardiology and neurology devices to 2023
• Competition and opportunities - see what affects the medical devices industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Opinions from our survey, seeing interviews with industry authorities.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

Avoid falling behind in knowledge or missing opportunities with our report. See how you could benefit your research, analyses, and decisions. Also find out how you can save time and gain recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for medical devices. You find data, trends and predictions there. Please order your report now.

1. Executive Summary

1.1 Industry Highlights
1.2 Overview of the Report Content
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Medical Devices

2. An Introduction to the Medical Device Industry

2.1 Classifying Medical Devices
2.1.1 The US Medical Devices Classification System
2.1.2 The EU Medical Devices Classification System
2.2 Regulation of Medical Devices
2.2.1 The US Approval and Regulation System
2.2.2 The EU Approval and Regulation System
2.2.2.1 Post-marketing Surveillance in the EU
2.3 Coronary Artery Disease and Coronary Stents
2.3.1 Bare Metal Stents
2.3.2 Drug Eluting Stents (DES)
2.3.3 Drugs Used in DES
2.3.3.1 Sirolimus: The first drug to be used on a DES
2.3.3.2 Everolimus
2.3.3.3 Zotarolimus
2.3.3.4 Paclitaxel: the only non-sirolimus deravative In the US market
2.4 Neuromodulation
2.4.1 Chronic Pain and Spinal Cord Stimulation
2.4.2 Parkinson's Disease and Deep Brain Stimulation
2.4.2.1 Parkinson's Disease
2.4.2.2 Deep Brain Stimulation
2.4.2.3 Epilepsy and Vagus Nerve Stimulation

3. The Global Medical Device Market 2013-2023

3.1 Medical Devices: Market Overview
3.1.1 Size of the Medical Device Market in 2012
3.1.2 Medical Devices: Revenue Analysis by Company, 2012
3.1.2.1 Johnson & Johnson: Largest Market Share in the Medical Device Sector
3.1.2.2 GE Healthcare: Strong Growth in Emerging Markets
3.1.2.3 Siemens Healthcare: Third Largest Medical Device Company in 2012
3.1.2.4 Medtronic: Largest Company Solely Manufacturing Medical Devices
3.1.2.5 Baxter International: Major Player in the Renal Devices Sector
3.1.2.6 Philips Healthcare: Specialist in Medical Imaging Systems
3.1.2.7 Roche: Major Player in the European Medical Device Market
3.1.2.8 Abbott Laboratories: Market Leader in the Coronary DES Sector
3.1.2.9 Stryker Corporation: Strong Growth in Neurovascular Business
3.1.2.10 Becton, Dickinson & Co.
3.1.2.11 Samsung: A New Entry Into The Market
3.2 World Medical Device Market Forecast, 2013-2017
3.3 World Medical Device Market Forecast, 2017-2023
3.4 Regional Medical Device Market Forecast, 2013-2023
3.4.1 US, EU5 and Japan - The Leading Regions in the Medical Device Market
3.4.1.1 The US Market: Represents Over a Third of the Global Market
3.4.1.2 The EU5 Markets: Fiscal Restrictions Affecting Market Growth
3.4.1.3 Japan: The Second Largest National Medical Device Market in the World
3.4.2 The Chinese and Indian Markets
3.4.2.1 China: Double Digit CAGR in 2013-2023
3.4.2.2 India: A Rapidly Growing Medical Device Market
3.4.3 Russia and Brazil: New Power Players in the Medical Device Global Market
3.4.3.1 The Russian Market
3.4.3.2 The Brazilian Market
3.4.4 The EU5 Medical Device Markets
3.4.4.1 Germany: The Biggest Medical Device Market in Europe
3.4.4.2 France: A Rapidly Rising over-65 Population
3.4.4.3 UK: An Import-led Market
3.4.4.4 Italy: Decentralisation of Medical Services will Drive Growth
3.4.4.5 Spain: Cost-Containment Measures Impacting Growth
3.5 Changing Market Shares by Region, 2012-2023

4. Issues Affecting the Medical Device Market

4.1 SWOT Analysis of the Medical Device Industry and Market, 2013-2023
4.2 Strengths
4.2.1 Strong Government Support Across Major International Markets
4.2.2 Sustained Market Segmentation
4.2.3 Large Number of Participating Companies
4.3 Weaknesses
4.3.1 The Market is Susceptible to Economic Pressures
4.3.2 Much of the Market Has Reached Maturity
4.4 Opportunities
4.4.1 An Aging Global Population
4.4.2 Personalised Medicine Providing Growth Opportunities
4.4.3 Regulatory Harmonisation Across Major International Markets
4.4.4 Increased Incidence and Prevalence of Many Diseases
4.4.5 Rapid Growth in Emerging Markets
4.5 Threats
4.5.1 Changes to Reimbursement Globally
4.5.2 Comparative Effectiveness Research as an Added Expense
4.5.3 US Medical Device Excise Tax
4.6 Porter's Five Force Analysis of the Medical Device Market
4.6.1 Power of Suppliers: Low
4.6.2 Threat of Substitutes: Low
4.6.3 Rivalry Among Competitors: High
4.6.4 Bargaining Power of Buyers: High
4.6.5 Threat of New Entrants: Low

5. The Cardiology Devices Market 2013-2023

5.1 Cardiology Devices: Market Overview
5.1.1 Cardiology Devices Market in 2012
5.1.2 Cardiology Devices Market Forecast, 2013-2023
5.2 The Drug Eluting Coronary Stent Market: Analysis & Forecast 2013-2023
5.2.1 The DES Market, 2012
5.2.2 The DES Market Forecast, 2013-2017
5.2.3 The DES Market Forecast, 2017-2023
5.3 Leading Coronary Stents: Product Analysis
5.3.1 Biomatrix (Biosensors International)
5.3.2 Xience Family of Everolimus-Eluting Stents (Abbott Vascular)
5.3.3 Taxus Paclitaxel-Eluting Stent (Boston Scientific)
5.3.4 Promus Everolimus-Eluting Stent (Boston Scientific)
5.3.5 Endeavor (Medtronic)
5.4 Coronary Stent Pipeline
5.4.1 Genous Combo (OrbusNeich)
5.4.2 Jactax (Boston Scientific)
5.4.3 Catania (CeloNova Biosciences)
5.4.4 MiStent SES (MiCell Technologies)
5.4.5 BioFreedom (Biosensors International)
5.4.6 Synergy (Boston Scientific)
5.5 SWOT Analysis of the DES Market, 2013-2023
5.5.1 Strengths
5.5.1.1 Competition: A Catalyst for DES Market Growth
5.5.1.2 DES: Proven Effectiveness over BMS
5.5.1.3 Continuous Innovation
5.5.1.3.1 Polyzene-F Coated Stents: Potential Game Changer for the Stent Market?
5.5.2 Weaknesses
5.5.2.1 The Success of DES Compared with Other Treatments
5.5.2.2 The Risk of Stent Thrombosis
5.5.3 Opportunities
5.5.3.1 Rising Incidences of Coronary Artery Disease
5.5.3.2 Dual Antiplatelet Therapy: An Avoidable Expense?
5.5.4 Threats
5.5.4.1 The DES Market is Still Emerging
5.5.4.2 US and Japan DES Markets are Dominated by a Small Number of Companies
5.5.4.3 The Stent May Become Secondary to the Eluted Drug

6. The Neurological Device Market 2013-2023

6.1. Neurological Devices: Market Overview
6.2 Neurological Device Market Forecast, 2013-2023
6.3 Neuromodulation Market Analysis
6.3.1 The Neuromodulation Market Forecast, 2013-2023
6.3.2 SCS Market Forecast, 2013-2017
6.3.3 SCS Market Forecast, 2017-2023
6.3.4 DBS Market Forecast, 2013-2017
6.3.5 DBS Market Forecast, 2017-2023
6.3.6 VNS Market Forecast, 2013-2017
6.3.7 VNS Market Forecast, 2017-2023
6.3.8 Other Neuromodulation Devices Forecast, 2013-2023
6.4 Changing Market Shares of the Leading Neuromodulation Segments
6.5 Neuromodulation Device Pipeline
6.5.1. NeuroPace
6.5.2 Apnex Medical
6.5.3 Intelect Medical (acquired by Boston Scientific Corporation)
6.5.4 CVRx
6.5.5. ImThera Medical
6.5.6 Devices Treating Obesity
6.5.6.1 IntraPace
6.5.6.2 EnteroMedics
6.5.6.3 MetaCure
6.6 SWOT Analysis of the Neuromodulation Device Industry, 2013-2023
6.6.1 Strengths
6.6.1.1 Provides a Safer Alternative
6.6.1.2 Neuromodulation Often Means Less Medication
6.6.1.3 Neuromodulation as a Cost-Effective Treatment Option
6.6.2 Weaknesses
6.6.2.1 Mechanisms are Not Fully Understood
6.6.2.2 Delayed FDA approvals
6.6.2.3 A Few Large Companies Dominate the Market
6.6.2.4 Devices Failing in Clinical Trials
6.6.3 Opportunities
6.6.3.1 Neuromodulation Market Set for Rapid Growth due to Expanding Disease Indications
6.6.3.2 Expansion into Emerging Markets
6.6.3.3 Increasing Prevalence of Neurological Diseases
6.6.3.4 The Potential of Personalised Medicine
6.6.4 Threats
6.6.4.1 Increasing Regulatory and Pricing Scrutiny
6.6.4.2 The Emergence of Stem Cell Therapies
6.6.4.3 SCS Faces Competition from Other Treatment Options

7. Expert Opinion

7.1 Interview with Dr. Simon Thomson, Consultant in Pain medicine and Neuromodulation, and President of the International Neuromodulation Society (INS)
7.1.1 The Fast Growing Neuromodulation Market
7.1.2 Potential Advancements in Neuromodulation Technology
7.1.3 Electro-ceuticals: Possible New Treatment?
7.1.4 Strategies To Tackle Negative Perception of Interventional Devices
7.1.5 Medical Devices Excise Tax: Friend or Foe?
7.1.6 Influencing Market Penetration of Neuromodulation Devices
7.1.7 Neuromodulation Market: Future Projection
7.2 Interview with Dr. Mateusz Zelewski, Chief Executive Officer, MetaCure
7.2.1 Current State of the Gastrostimulation Market
7.2.2 Impact of New Tax Legislations
7.2.3 MetaCure's DIAMOND System: New Model
7.2.4 Changing Perception of Interventional Diabetology
7.2.5 Product Distribution and Potential Collaborations
7.2.6 Future Projection for the Gastrostimulation Sector
7.3 Interview with Spokesperson From Boston Scientific Corporation
7.3.1 Current Perspective on the Medical Devices Industry
7.3.2 Boston Scientific's Position in the DES Market
7.3.3 FDA Approval: An Unnecessarily Long-winded Process?
7.3.4 Boston Scientific's Neuromodulation Market Consolidation and Growth Strategies
7.3.5 Influencing Public Oppinion on Interventional Devices
7.3.6 US Excise Tax: A Restraint to Product Innovation?
7.3.7 The Future of the Medical Devices Market

8. Conclusions

8.1 The Medical Device Industry, 2013-2023
8.1.1 Personalised Medicine: Possible Growth Driver in the Coming Decade
8.1.2 Emerging Markets: Urbanisation-Driven Growth
8.2 The Coronary Stent Market, 2013-2023
8.3 The Neurology Market 2013-2023
8.3.1 Neuromodulation: A Rapidly Growing Sector
8.3.2 New Indications Driving Neuromodulation Market Growth
8.4 Alternative Treatment Options: Potential Restraint on Market Growth

List of Tables

Table 2.1 The US Classification of Medical Devices
Table 2.2 The EU Classification of Medical Devices
Table 3.1 The Medical Devices Market: Revenues ($bn) and Market Shares (%) by Sector, 2012
Table 3.2 The Top Medical Device Companies: Revenues ($bn) and Market Shares (%), 2012
Table 3.3 Johnson & Johnson Medical Devices and Diagnostics: Revenue ($bn) and Revenue Shares (%) by Franchise, 2012
Table 3.4 Johnson & Johnson: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.5 GE Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.6 Siemens Healthcare Medical Devices: Revenues ($bn) and Revenue Shares (%) by Region, 2011 and 2012
Table 3.7 Siemens Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.8 Medtronic: Revenues ($bn) and Revenue Shares (%) by Franchise, 2012
Table 3.9 Medtronic: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 3.10 Medtronic: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.11 Baxter International: Revenues ($bn) and Revenue Shares (%) by Business Sector, 2012
Table 3.12 Baxter International: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 3.13 Baxter International: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.14 Philips Healthcare: Revenues ($bn) and Revenue Shares (%) by Sector, 2012
Table 3.15 Philips Healthcare Medical Devices: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 3.16 Philips Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.17 Roche Medical Devices and Diagnostics: Revenues ($bn) and Revenue Shares (%) by Sector, 2012
Table 3.18 Roche: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.19 Abbott Medical Devices and Diagnostics: Revenues ($bn) and Revenue Shares (%) by Region, 2012
Table 3.20 Abbott Laboratories: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.21 Stryker Corporation Medical Devices: Total Revenue Shares (%) by Franchise, 2012
Table 3.22 Stryker Corporation: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.23 Becton Dickinson & Co: Medical Devices Revenues ($bn) and Revenue Shares (%) by Sector, 2012
Table 3.24 Becton Dickinson & Co: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 3.25 The Global Medical Device Market: Drivers and Restraints, 2013-2023
Table 3.26 The Global Medical Devices Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2012-2017
Table 3.27 The Global Medical Devices Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2017-2023
Table 3.28 The EU5 Medical Devices Markets: Revenues ($bn) and Market Shares (%) by Country, 2012
Table 3.29 The EU5 Medical Devices Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2012-2017
Table 3.30 The EU5 Medical Devices Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2017-2023
Table 3.31 The Medical Device Market: Revenue ($bn) by Region, 2012, 2017 and 2023
Table 3.32 The Medical Device Market: Market Shares (%) by Region, 2012, 2017 and 2023
Table 4.1 SWOT Analysis for the Medical Device Industry, 2013-2023
Table 5.1 Cardiology Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.2 Cardiology Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 5.3 Drug Eluting Stents: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 5.4 Drug Eluting Stents: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 5.5 Growth Drivers and Restraints for the Drug Eluting Stent Market, 2013-2023
Table 5.6 Boston Scientific's Taxus Stent Revenue ($bn) by Region, 2011 & 2012
Table 5.7 Coronary Stent Development Pipeline, 2013
Table 5.8 SWOT Analysis for the DES Market, 2013-2023
Table 6.1 Neurological and Neuromodulation Markets: Revenue ($bn) by Sector, 2012
Table 6.2 Neurological Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.3 Neurological Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 6.4 Neuromodulation Devices: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2012-2017
Table 6.5 Neuromodulation Devices Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2017-2023
Table 6.6 SCS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.7 SCS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 6.8 DBS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.9 DBS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 6.10 VNS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
Table 6.11 VNS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
Table 6.12 Other Neuromodulation Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
Table 6.13 Neuromodulation Devices: Market Shares (%) by Sector, 2012-2023
Table 6.14 Neuromodulation Devices: Industry Pipeline, 2013
Table 6.15 SWOT Analysis of the Neuromodulation Devices Industry, 2013-2023

List of Figures

Figure 2.1 The Structure of Sirolimus
Figure 2.2 The Structure of Everolimus
Figure 2.3 The Structure of Zotarolimus
Figure 2.4 The Structure of Paclitaxel
Figure 3.1 The Medical Device Market: Market Shares (%) by Sector, 2012
Figure 3.2 Johnson & Johnson Medical Devices and Diagnostics: Revenue Shares (%) by Franchise, 2012
Figure 3.3 Johnson & Johnson Medical Devices and Diagnostics: Revenue ($bn) by Franchise, 2012
Figure 3.4 Johnson & Johnson: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.5 GE Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.6 Siemens Healthcare Medical Devices: Revenue Shares (%) by Region, 2012
Figure 3.7 Siemens Healthcare Medical Devices: Revenue ($bn) by Region, 2011 and 2012
Figure 3.8 Siemens Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.9 Medtronic: Revenue Shares (%) by Franchise, 2012
Figure 3.10 Medtronic: Revenue ($bn) by Region, 2012
Figure 3.11 Medtronic: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.12 Baxter International: Revenues ($bn) by Business Sector, 2012
Figure 3.13 Baxter International: Revenue Shares (%) by Region, 2012
Figure 3.14 Baxter International: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.15 Philips Healthcare Medical Devices: Revenue Shares (%) by Sector, 2012
Figure 3.16 Philips Healthcare: Revenues ($bn) by Region, 2012
Figure 3.17 Philips Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.18 Roche Medical Devices and Diagnostics: Revenue ($bn) by Sector, 2012
Figure 3.19 Roche: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.20 Abbott Medical Devices and Diagnostics: Revenue ($bn) by Region, 2012
Figure 3.21 Abbott Medical Devices and Diagnostics: Revenue Shares (%) by Region, 2012
Figure 3.22 Abbott Laboratories: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.23 Stryker Corporation Medical Devices: Total Revenue Shares (%) by Franchise, 2012
Figure 3.24 Stryker Corporation: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.25 Becton Dickinson & Co: Medical Devices Revenue Shares (%) by Sector, 2012
Figure 3.26 Becton Dickinson & Co: Medical Devices Revenue Forecast ($bn), 2012-2023
Figure 3.27 The Global Medical Devices Market: Revenue Forecast ($bn), 2012-2017
Figure 3.28 The Global Medical Devices Market: Revenue Forecast ($bn), 2017-2023
Figure 3.29 US, EU5 and Japan Medical Devices Markets: Revenue Forecast ($bn), 2012-2017
Figure 3.30 US, EU5 and Japan Medical Devices Markets: Revenue Forecast ($bn), 2017-2023
Figure 3.31 China and India: Medical Devices Revenue Forecast ($bn), 2012-2017
Figure 3.32 China and India: Medical Devices Revenue Forecast ($bn), 2017-2023
Figure 3.33 Brazil and Russia: Medical Devices Revenue Forecast ($bn), 2012-2017
Figure 3.34 Brazil and Russia: Medical Devices Revenue Forecast ($bn), 2017-2023
Figure 3.35 The EU5 Medical Devices Markets: Market Shares (%) by Country, 2012
Figure 3.36 The EU5 Medical Devices Markets: Revenue Forecast ($bn), 2012-2017
Figure 3.37 The EU5 Medical Devices Markets: Revenue Forecast ($bn), 2017-2023
Figure 3.38 Medical Device Market: Revenue ($bn) by Region, 2013, 2017 and 2023
Figure 3.39 The Medical Devices Market: Market Shares (%) by Region, 2012
Figure 3.40 The Medical Devices Market: Market Shares (%) by Region, 2017
Figure 3.41 The Medical Devices Market: Market Shares (%) by Region, 2023
Figure 5.1 Cardiology Devices: Market Revenue Forecast ($bn), 2012-2017
Figure 5.2 Cardiology Devices: Market Revenue Forecast ($bn), 2017-2023
Figure 5.3 Drug Eluting Stents: Market Revenue Forecast ($bn), 2012-2017
Figure 5.4 Drug Eluting Stents: Market Revenue Forecast ($bn), 2017-2023
Figure 5.5 Boston Scientific's Taxus Stent Revenue ($bn) by Region, 2011 & 2012
Figure 6.1 Neurological Devices: Market Revenue Forecast ($bn), 2012-2017
Figure 6.2 Neurological Devices: Market Revenue Forecast ($bn), 2017-2023
Figure 6.3 Neuromodulation Devices: Revenue Forecast ($bn), 2012-2017
Figure 6.4 Neuromodulation Devices: Revenue Forecast ($bn), 2017-2023
Figure 6.5 SCS Devices: Revenue Forecast ($bn), 2012-2017
Figure 6.6 SCS Devices: Revenue Forecast ($bn), 2017-2023
Figure 6.7 DBS Devices: Revenue Forecast ($bn), 2012-2017
Figure 6.8 DBS Devices: Revenue Forecast ($bn), 2017-2023
Figure 6.9 VNS Devices: Revenue Forecast ($bn), 2012-2017
Figure 6.10 VNS Devices: Revenue Forecast ($bn), 2017-2023
Figure 6.11 Other Neuromodulation Devices: Revenue Forecast ($bn), 2012-2023
Figure 6.12 Neuromodulation Devices: Market Shares (%) by Sector, 2012
Figure 6.13 Neuromodulation Devices: Market Shares (%) by Sector, 2017
Figure 6.14 Neuromodulation Devices: Market Shares (%) by Sector, 2023

Companies Listed

Abbott Laboratories
Angiotech Pharmaceuticals
Apnex Medical Inc
Association of Indian Medical Device Industry (AIMED)
Baxter International
Becton Dickinson & Co
Biosensors International
Biotronik SE & Co
Boston Scientific
Brazilian National Agency for Sanitary Surveillance (ANVISA)
Bristol Myers Squibb
CeloNova BioSciences Inc
Center for Devices and Radiological Health (CDRH) [US]
Central Drug Standard Control Organisation (CDSCO) [India]
Cerbomed
Cerebral Rx
China Food and Drug Administration (CFDA)
ClearStream Technologies
Cochlear Ltd.
Conor Medsystems Inc
Cordis Corporation
CVRx Inc
Cyberonics Inc.
DePuy Inc
Economic Committee for Medical Products [France]
ElectroCore
EnteroMedics Inc
Ethicon Endo-Surgery Inc
Eucomed
European Commission (EC)
Food & Drug Administration (FDA) [US]
GE Healthcare
Gemeinsame Bundesausschuss (G-BA) [Germany]
GlaxoSmithKline (GSK)
Global Harmonisation Task Force (GHTF)
Guidant Corporation
Impulse Dynamics
ImThera Medical Inc
Insightra Medical
Intelect Medical Inc
International Medical Device Regulators Forum (IMDRF)
International Neuromodulation Society (INS)
IntraPace Inc
Johnson & Johnson (J&J)
JW Medical Systems
KangHui Medical
Kiestra Lab Automation
Labcoat Ltd
Lupin Pharmaceuticals Inc
Medison Co Ltd
Medical Device Regulatory Authority (MDRA) [India]
Medtronic Inc
MetaCure Inc
MiCell Technologies Inc
Ministry of Health, Labour, and Welfare (MHLW) [Japan]
MIV Therapeutics Inc
National Epilepsy Foundation [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
NeuroPace Inc
Northstar Neuroscience Inc
Novartis
OrbusNeich
Ortho-Clinical Diagnostics Inc
Patient-Centered Outcomes Research Institute (PCORI) [US]
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Pfizer
Philips Healthcare
Roszdravnadzor [Russia]
Roche
Samsung
Sanofi-aventis
Servizio Sanitario Nazionale (SSN) [Italy]
Siemens Healthcare
Sistema Unico de Saude (SUS) [Brazil]
St Jude Medical
St. Michael's Hospital, Toronto, Canada
Stryker Corporation
Synthes
Terumo Medical Corporation
Teva Pharmaceutical Industries Ltd
Third Wave Technologies Inc
Transneuronix Inc
Trauson Holding
United Nations (UN)
United State Patent and Trademark Office (USPTO)
UCB Biopharma
Vitality Devices
World Health Organisation (WHO)

Read the full report:
Medical Devices Industry and Market Prospects 2013-2023
http://www.reportbuyer.com/pharma_healthcare/medical_devices/medical_devices_industry_market_prospects_2012_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE REPORTBUYER.COM (Channels Group)

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DX World EXPO, LLC, a Lighthouse Point, Florida-based startup trade show producer and the creator of "DXWorldEXPO® - Digital Transformation Conference & Expo" has announced its executive management team. The team is headed by Levent Selamoglu, who has been named CEO. "Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation," he said in making the announcement.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that Conference Guru has been named “Media Sponsor” of the 22nd International Cloud Expo, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to gre...
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
"ZeroStack is a startup in Silicon Valley. We're solving a very interesting problem around bringing public cloud convenience with private cloud control for enterprises and mid-size companies," explained Kamesh Pemmaraju, VP of Product Management at ZeroStack, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Large industrial manufacturing organizations are adopting the agile principles of cloud software companies. The industrial manufacturing development process has not scaled over time. Now that design CAD teams are geographically distributed, centralizing their work is key. With large multi-gigabyte projects, outdated tools have stifled industrial team agility, time-to-market milestones, and impacted P&L stakeholders.
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Enterprises are adopting Kubernetes to accelerate the development and the delivery of cloud-native applications. However, sharing a Kubernetes cluster between members of the same team can be challenging. And, sharing clusters across multiple teams is even harder. Kubernetes offers several constructs to help implement segmentation and isolation. However, these primitives can be complex to understand and apply. As a result, it’s becoming common for enterprises to end up with several clusters. Thi...